These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 34990047

  • 1. Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial.
    Kaminski H, Kamar N, Thaunat O, Bouvier N, Caillard S, Garrigue I, Anglicheau D, Rérolle JP, Le Meur Y, Durrbach A, Bachelet T, Savel H, Coueron R, Visentin J, Del Bello A, Pellegrin I, Déchanet-Merville J, Merville P, Thiébaut R, Couzi L.
    Am J Transplant; 2022 May; 22(5):1430-1441. PubMed ID: 34990047
    [Abstract] [Full Text] [Related]

  • 2. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
    Basso G, Felipe CR, Cristelli MP, Mansur Siliano J, Viana L, Ferreira Brigido AN, Stopa Martins SB, de Castro Lima Santos DW, Aguiar WF, Tedesco-Silva Junior H, Medina-Pestana JO.
    Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
    [Abstract] [Full Text] [Related]

  • 3. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials.
    Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, Shihab FS.
    Am J Transplant; 2011 Nov; 11(11):2453-62. PubMed ID: 21812923
    [Abstract] [Full Text] [Related]

  • 4. Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis.
    Manière L, Noble J, Terrec F, Bennani HN, Chevallier E, Janbon B, Germi R, Bugnazet M, Imerzoukene F, Malvezzi P, Rostaing L, Jouve T.
    Int Urol Nephrol; 2021 Mar; 53(3):591-600. PubMed ID: 33058036
    [Abstract] [Full Text] [Related]

  • 5. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, Aguiar W, Campos E, Gerbase-DeLima M, Franco M, Medina-Pestana J.
    Am J Transplant; 2015 Oct; 15(10):2655-64. PubMed ID: 25988935
    [Abstract] [Full Text] [Related]

  • 6. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP, Esmeraldo RM, Pinto CM, Sandes-Freitas TV, Felipe C, Lobo CF, Viana L, Mansur J, Stopa S, Santos DWC, Grenzi PC, Aguiar WF, Tedesco-Silva H, Pestana JOM.
    Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
    [Abstract] [Full Text] [Related]

  • 7. A Head-to-head Comparison of De Novo Sirolimus or Everolimus Plus Reduced-dose Tacrolimus in Kidney Transplant Recipients: A Prospective and Randomized Trial.
    Toniato de Rezende Freschi J, Cristelli MP, Viana LA, Ficher KN, Nakamura MR, Proença H, Dreige YC, de Marco R, de Lima MG, Foresto RD, Aguiar WF, Medina-Pestana J, Tedesco-Silva H.
    Transplantation; 2024 Jan 01; 108(1):261-275. PubMed ID: 37525373
    [Abstract] [Full Text] [Related]

  • 8. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.
    Rittà M, Costa C, Solidoro P, Sidoti F, Libertucci D, Boffini M, Rinaldi M, Baldi S, Cavallo R.
    Antiviral Res; 2015 Jan 01; 113():19-26. PubMed ID: 25446337
    [Abstract] [Full Text] [Related]

  • 9. Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results.
    Hauser IA, Marx S, Sommerer C, Suwelack B, Dragun D, Witzke O, Lehner F, Schiedel C, Porstner M, Thaiss F, Neudörfl C, Falk CS, Nashan B, Sester M.
    Eur J Immunol; 2021 Apr 01; 51(4):943-955. PubMed ID: 33306229
    [Abstract] [Full Text] [Related]

  • 10. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
    Nanmoku K, Shinzato T, Kubo T, Shimizu T, Kimura T, Yagisawa T.
    Transplant Proc; 2018 May 01; 50(4):1050-1055. PubMed ID: 29631750
    [Abstract] [Full Text] [Related]

  • 11. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
    de Sandes-Freitas TV, Pinheiro PMA, Sales MLMBO, Girão CM, Campos ÉF, Esmeraldo RM.
    Transpl Int; 2018 Dec 01; 31(12):1345-1356. PubMed ID: 29969826
    [Abstract] [Full Text] [Related]

  • 12. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul 01; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 13. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T, Borges K, Williams A, Banh T, Vasilevska-Ristovska J, Allen U, Parekh RS, Hébert D.
    Transplantation; 2018 Aug 01; 102(8):1391-1396. PubMed ID: 29377877
    [Abstract] [Full Text] [Related]

  • 14. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
    Radtke J, Dietze N, Spetzler VN, Fischer L, Achilles EG, Li J, Scheidat S, Thaiss F, Nashan B, Koch M.
    Transpl Infect Dis; 2016 Feb 01; 18(1):79-88. PubMed ID: 26707694
    [Abstract] [Full Text] [Related]

  • 15. Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus.
    Devresse A, Leruez-Ville M, Scemla A, Avettand-Fenoel V, Morin L, Lebreton X, Tinel C, Amrouche L, Lamhaut L, Timsit MO, Zuber J, Legendre C, Anglicheau D.
    Transpl Infect Dis; 2018 Apr 01; 20(2):e12846. PubMed ID: 29360195
    [Abstract] [Full Text] [Related]

  • 16. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
    Ferreira AN, Felipe CR, Cristelli M, Viana L, Mansur J, de Paula M, Wagner D, de Marco R, Gerbase-DeLima M, Proença H, Aguiar W, Medina-Pestana J, Tedesco-Silva Junior H.
    Transpl Int; 2019 Nov 01; 32(11):1127-1143. PubMed ID: 31278785
    [Abstract] [Full Text] [Related]

  • 17. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF, RAD A2411 Study Investigators.
    Transpl Infect Dis; 2010 Feb 01; 12(1):23-30. PubMed ID: 19744284
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 19. Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus Infection: A Short-Term Pharmacoeconomic Evaluation (12 Months).
    Felipe C, Tedesco-Silva H, Ferreira Brigido A, Bessa A, Ruppel P, Hiramoto L, de Paula M, Cristelli M, Stopa S, Mansur J, Viana L, Fahham L, Pepe C, Medina-Pestana J.
    Value Health Reg Issues; 2017 Dec 16; 14():108-115. PubMed ID: 29254534
    [Abstract] [Full Text] [Related]

  • 20. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J, TRANSFORM investigators.
    Am J Transplant; 2019 Nov 16; 19(11):3018-3034. PubMed ID: 31152476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.